Multiple Myeloma: Unmet Needs and Future Directions in Care
After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.
CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond
Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.
Combination Strategies With Bispecifics in Multiple Myeloma
Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.
Bispecifics in Multiple Myeloma: Adverse Event Management
Expert perspectives on adverse event management in patients on bispecific therapy for multiply relapsed multiple myeloma.
Bispecifics in Multiple Myeloma: Dosing and Transition of Care
A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.
Multiple Myeloma: Sequencing Novel Therapies in Later Lines of Treatment
Focused discussion on the sequencing of bispecifics or CAR T-cell therapies in patients with multiply relapsed multiple myeloma.
Patient Scenario: Bispecifics in MM After Multiple Prior Lines of Therapy
Centering discussion on a patient scenario of multiply relapsed multiple myeloma, panelists consider available novel therapies within the treatment landscape.
Factors in Selecting Therapy at First Relapse in Multiple Myeloma
Shared insight from experts in multiple myeloma on patient and disease characteristics that inform selection of best therapy at first relapse.
Patient Scenario: Treatment Options in MM at First Relapse
Key opinion leaders review the case of a patient at first relapse with multiple myeloma and consider optimal treatment strategies in this setting.
Treatment Duration in Patients With Newly Diagnosed Multiple Myeloma
A panel of experts reflects on treatment duration and its role in optimizing management of patients with newly diagnosed multiple myeloma.
Determining Frailty in Patients With Newly Diagnosed Multiple Myeloma
Focused discussion on the importance of patient frailty in determining optimal treatment pathways in newly diagnosed multiple myeloma.
Treatment Options for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Expert perspectives on the treatment armamentarium for transplant-ineligible newly diagnosed multiple myeloma.
Impact of Risk Status on Treatment Pathways in Newly Diagnosed Multiple Myeloma
Shared insight on the impact risk status has on the selection of optimal therapy for patients with newly diagnosed multiple myeloma.
Induction Therapy Regimens for Transplant-Eligible NDMM
Key opinion leaders on multiple myeloma management review available induction therapy regimens in the transplant-eligible setting.
NDMM: Identifying Patient and Disease Factors to Select Appropriate Therapy
Comprehensive insight on patient and disease characteristics that help to inform best available therapy for patients with newly diagnosed multiple myeloma.
What is the Role of Transplant in Newly Diagnosed Multiple Myeloma?
Expert panelists reflect on the continuing role of stem cell transplant in patients with newly diagnosed multiple myeloma.
Influencing Factors to Initially Targeting BCMA in MM
Ongoing Approaches Toward Targeting BCMA
Next Steps for Use of Belantamab in Clinical Practice
DREAMM-2 Trial Regimen: Safety Updates and Dose Delay
Management of Ocular Events From DREAMM-2 Regimen
DREAMM-2 Trial Regimen Safety Profile
DREAMM-2 Trial Efficacy Data and Recent FDA Approval
The Rationale for Targeting BCMA in Multiple Myeloma
Treatment Approach for R/R Multiple Myeloma
Future of BCMA-Targeted Therapies in Multiple Myeloma
Bispecific Antibodies for Multiple Myeloma
Differentiating among CAR T Products for Multiple Myeloma
Development of CAR T Cells in Multiple Myeloma
Using Antibody-Drug Conjugates in Multiple Myeloma
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512